Rich-Henry Schabowsky, Ph.D., J.D.
CEO & President
Rich-Henry Schabowsky, Ph.D., J.D.
Vibha Jawa, Ph.D., FAAPS
CSO
Vibha Jawa, Ph.D., FAAPS
Dr. Vibha Jawa joined EpiVax in 2025 as Chief Scientific Officer where she leads scientific strategy, guiding research efforts and helping shape the company’s approach to new therapies and technologies. Previously, she held the position of Executive Director in the Translational Medicine organization at Bristol Myers Squibb. In this role, she led biotherapeutic and cell /gene therapy bioanalytical (BA) function, supporting PK and immunogenicity related preclinical and clinical related support. She provided strategic and scientific oversight for BMS developmental portfolio. Vibha was at Merck for 4 years where she led the Predictive and Clinical Immunogenicity group and at Amgen for 14 years supporting Discovery to Development for biotherapeutics.
Vibha has 20+ years of experience in diverse fields of biologics , vaccine development and gene therapy with successful support of 20 + IND, BLA and MAA filings. Vibha is a recognized leader in Bioanalysis and Immunogenicity with 100+ peer-reviewed publications and serves as a Reviewer and Editor for The AAPS Journal and J. Pharm Sci. She is an active member of multiple scientific societies and consortiums ( IQ, SC space Consortium and EIP) .Within AAPS, she is Track Chair of Land O Lakes Bioanalysis Meeting, Chair of the Cell and Gene therapy Bioanalysis and Biomarker working group, Steering Committee member of the Therapeutic Product Immunogenicity Community, past chair of Immunogenicity Risk Assessment and Mitigation Community and leads the IQ Consortium for Cell/Viral/Gene therapies. She was recognized as the AAPS Fellow 2022. Vibha is the President of Steampark a nonprofit promoting STEM based learning in underserved communities. She also likes to mentor high school students on STEM related projects and early career scientists in her free time.
Guilhem Richard, Ph.D.
CTO
Guilhem Richard, Ph.D.
Guilhem is Chief Technology Officer at EpiVax, Inc. and has over 10 years of experience in computational immunology and vaccinology. Dr. Richard joined the EpiVax immunoinformatics team in 2014, developing new models for understanding the interaction between the immune system and protein sequences, while supporting EpiVax’s commercial and research programs. He spearheaded the development of a new computational platform for the development of personalized, neoantigen-based cancer vaccines (Ancer®), and conducted subsequent translational work at EpiVax’s subsidiary company, EpiVax Therapeutics, Inc., where he served as Chief Scientific Officer/Chief Technology Officer from 2019 to 2024. Dr. Richard has been leading innovation efforts at EpiVax since 2024 and is overseeing the development of its next generation of immunoinformatics tools. Dr. Richard holds a Ph.D. in Bioinformatics from Boston University and a M.Eng. in Bioinformatics and Modeling from the National Institute of Applied Sciences (INSA) of Lyon, France.
Christine Boyle, Ph.D.
CSOO
Christine Boyle, Ph.D.
Christine is the Chief Scientific Operations Officer at EpiVax where she provides leadership to the research programs and project management, facilitating operations within the preclinical scientific teams. Christine earned her PhD in Immunology and Virology from the University of Massachusetts Medical School in 2000 and graduated from Smith College in 1990. She joined EpiVax in 2011, as a project manager in the Vaccine group where she managed multiple grant and internally funded programs, and collaborations focusing on T-cell epitope-driven vaccine development using EpiVax.
She currently oversees and manages the complex scientific portfolio at EpiVax and anticipates the group’s future needs to develop capabilities aligned with the needs and vision of the senior leadership team. She provides guidance and oversight to scientific teams for the administration, development and preparation of research proposals and contracts that continue to grow EpiVax’ impressive grant portfolio and scientific discovery. Through her leadership, she builds an environment to empower and enable scientific team members to contribute to and invest in group success by building teams across functions with individuals who have the right skills and experience to deliver on key organizational initiatives. She is a skilled problem solver able to identify, evaluate, develop, recommend and/or negotiate novel solutions to meet critical project needs.
Brad Crevier, J.D.
CFO
Brad Crevier, J.D.
Brad is responsible for managing all strategic and operational financial objectives at EpiVax. His most recent financial management experience was as Assistant Treasurer at audio technology company Sonos, where he oversaw the team responsible for all operational treasury aspects of the public company. He also held the positions of Director of Treasury and Director of International Tax and was part of the team that brought the company public. Additionally, Brad has previous experience at private equity owned The Rockport Group and the Boston offices of Deloitte and PwC. He is a bar-certified attorney with a JD and MS Accounting/MBA from Northeastern University.
As a senior global finance executive, Brad brings deep expertise in corporate and capital structuring, finance policy implementation, treasury operations, tax strategy, and risk management across diverse business landscapes.
Matthew Ardito
Director of IT
Matthew Ardito
In his early years at EpiVax, Matthew Ardito assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications. In 2021, Matt was promoted again to Director of IT, where he is responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax.
Aimee Mattei, M.S.
Director of Immunology & Immunoinformatics
Aimee Mattei, M.S.
Sarah Moniz
Director of Business Development & Marketing
Sarah Moniz
Sarah Moniz is Director of Business Development and Marketing at EpiVax, where she leads the company’s commercial strategy and customer engagement efforts.
With nearly nine years at EpiVax, Sarah brings deep institutional knowledge of the company’s technologies and services. She has developed a strong understanding of customer needs in her work supporting the translation of the company’s scientific expertise in integrating computational analysis and in vitro assessment applications across the product lifecycle into impactful solutions for global pharmaceutical and biotech organizations in therapeutic and vaccine development.
In her role, Sarah partners closely with EpiVax’s scientific, technical, and executive leadership to shape go-to-market strategy, launch new services, and build long-term customer partnerships. Sarah’s team oversees business development, marketing, sales, account management, and revenue operations, ensuring a cohesive and effective commercial experience from first engagement through ongoing collaboration and supporting EpiVax’s mission to deliver innovative, reliable solutions that accelerate and de-risk therapeutic and vaccine development.
Leaya Martelli
Director of Human Resources
Leaya Martelli
As Director of Human Resources at EpiVax, Leaya enjoys being a strategic partner to the executive suite and all levels across EpiVax. Leaya is a department of one, and is responsible for employee development and engagement, compensation modeling and planning, benefit plan design, talent acquisition/recruiting, performance management, training and policy development, and succession planning.
Leaya started her career in recruiting, where she gained a valuable understanding of people management, business skills, communication, and patience. She later went on to start her own life science boutique recruitment firm, Place Boston, with two other women for nearly a decade. Leaya was later recruited by a former client to help develop a new start-up company, combining tech and life science recruitment, with a matching algorithm. Once the company, Clora, was fully established and had received Series A funding, Leaya transitioned into working directly for a life science company and has been with EpiVax since then. Leaya has a passion for helping others and her goal is to help businesses and employees in the life science industry expand, while advocating for both the company and the employees.
Leaya has a bachelor’s degree in business administration from Dean College with a concentration in Human Resources, and an additional certificate in Human Resource Management.